Anti-Obesity Meds' Impact on Allurion Program

New research highlights the positive impact of anti-obesity medications, particularly GLP-1s, on the Allurion Program, with the global market for anti-obesity medications projected to reach $100 billion by 2030. The research indicates a positive influence of GLP-1 growth on Allurion Program awareness among healthcare professionals and patients. Allurion's CEO, Shantanu Gaur, emphasized the potential of the Allurion Program as an ideal first-line treatment for combating obesity.